ExodusPoint Capital Management LP acquired a new stake in Novavax, Inc. (NASDAQ:NVAX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 334,146 shares of the biopharmaceutical company's stock, valued at approximately $2,687,000. ExodusPoint Capital Management LP owned approximately 0.21% of Novavax as of its most recent SEC filing.
A number of other hedge funds have also recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in shares of Novavax by 1.9% during the 4th quarter. Vanguard Group Inc. now owns 15,726,250 shares of the biopharmaceutical company's stock worth $126,439,000 after acquiring an additional 296,181 shares in the last quarter. Shah Capital Management increased its position in Novavax by 13.6% in the fourth quarter. Shah Capital Management now owns 11,148,846 shares of the biopharmaceutical company's stock worth $89,637,000 after purchasing an additional 1,333,305 shares during the last quarter. State Street Corp lifted its position in Novavax by 26.7% during the third quarter. State Street Corp now owns 7,687,951 shares of the biopharmaceutical company's stock valued at $97,099,000 after purchasing an additional 1,621,772 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Novavax by 4.4% in the 4th quarter. Geode Capital Management LLC now owns 3,657,695 shares of the biopharmaceutical company's stock worth $29,415,000 after buying an additional 155,206 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Novavax by 3.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,365,414 shares of the biopharmaceutical company's stock worth $10,978,000 after buying an additional 39,906 shares during the last quarter. Institutional investors own 53.04% of the company's stock.
Analyst Ratings Changes
A number of equities research analysts have issued reports on NVAX shares. TD Cowen upgraded Novavax to a "hold" rating in a research report on Thursday, February 27th. BTIG Research initiated coverage on shares of Novavax in a research note on Friday, February 28th. They set a "buy" rating and a $19.00 price objective for the company. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, Novavax currently has an average rating of "Hold" and a consensus price target of $18.00.
Get Our Latest Research Report on Novavax
Novavax Stock Up 7.9 %
NASDAQ:NVAX traded up $0.43 during midday trading on Friday, hitting $5.86. The stock had a trading volume of 6,647,848 shares, compared to its average volume of 8,208,896. The stock has a 50-day moving average of $7.48 and a 200 day moving average of $8.82. The company has a market capitalization of $942.55 million, a price-to-earnings ratio of -2.59, a PEG ratio of 2.85 and a beta of 3.15. Novavax, Inc. has a one year low of $3.81 and a one year high of $23.86.
Novavax (NASDAQ:NVAX - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.24. The firm had revenue of $88.31 million for the quarter, compared to analysts' expectations of $85.48 million. During the same quarter in the prior year, the business posted ($1.44) EPS. On average, sell-side analysts anticipate that Novavax, Inc. will post -1.46 earnings per share for the current fiscal year.
About Novavax
(
Free Report)
Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.
Read More
Before you consider Novavax, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novavax wasn't on the list.
While Novavax currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
